Prevalence of Silent Atherosclerosis across Adult Life
Authors, Journal, Affiliations, Type, DOI
- Henning Bundgaard, Inés García-Lunar, Klaus F. Kofoed, Rasmus Hasselbalch, and co-authors for the REACT Investigators; lead sites Rigshospitalet, Copenhagen University Hospital and Centro Nacional de Investigaciones Cardiovasculares, Madrid.
- Multicentre Danish–Spanish prospective cohort study; 50.3% recruited in Spain and 49.7% in Denmark.
- The New England Journal of Medicine, 2026;395:1818-1829 (November 5, 2026 issue).
- Type: prospective, cross-sectional analysis of a population-based imaging cohort.
- DOI: 10.1056/NEJMoa2609059. ClinicalTrials.gov: NCT06692127.
- Funded by the Novo Nordisk Foundation, with in-kind contributions from Philips Healthcare and Zeiss.
Overview
REACT imaged 16,808 adults aged 18–70 years without known atherosclerotic cardiovascular disease using three-dimensional carotid and femoral ultrasound plus coronary CT angiography. Silent atherosclerosis was present in 57.1% overall, already detectable in about 1 in 13 participants aged 18–29, and present in nearly all participants aged 60–70. Prevalence rose earlier in men and more steeply in women after age 40; plaque volume increased exponentially with age, and involvement became increasingly multiterritorial. Conventional SCORE2 risk classification identified only a small minority of people with established silent disease, and coronary plaque frequently occurred without detectable calcium at younger ages.
Keywords
Subclinical atherosclerosis, silent atherosclerosis, carotid ultrasound, femoral ultrasound, coronary CT angiography, coronary artery calcium, prevalence, primary prevention, SCORE2
Key Takeaways
Background and Rationale
- Atherosclerosis can begin in early adulthood and remain clinically silent for decades.
- Previous imaging cohorts mostly enrolled middle-aged and older adults; younger-adult data were small, selected or based on surrogate markers rather than direct plaque quantification.
- The study was designed to provide an age- and sex-specific atlas of silent atherosclerosis across adult life, its vascular distribution and its plaque volume.
Methods
- Adults 18–70 years without known clinical ASCVD (myocardial infarction, ischaemic stroke, peripheral artery disease or prior coronary revascularization); symptoms such as angina or claudication were not formal exclusions.
- Prespecified age strata: approximately 2,000 participants each aged 18–29 and 60–70, and approximately 4,000 each aged 30–39, 40–49 and 50–59, balanced by country and sex.
- Carotid and femoral atherosclerosis assessed by three-dimensional vascular ultrasound; coronary atherosclerosis by coronary CT angiography; coronary calcium by noncontrast CT.
- Primary outcome: plaque in at least one examined vascular territory.
- Key secondary outcomes: plaque in each territory, plaque volume per territory, global peripheral plaque volume, coronary plaque volume and coronary artery calcium score.
- SCORE2 estimated 10-year cardiovascular risk in participants aged 40–69.
Participants
- 16,808 enrolled November 2024 to June 2026; mean age 45±12 years; 51.4% women.
- Imaging available for carotid arteries in 16,317, femoral arteries in 15,844 and coronary arteries in 14,140; complete three-territory imaging in 13,186 (the primary prevalence population).
- The cohort appeared representative of the general populations of Spain and Denmark.
Prevalence
- Silent atherosclerosis in at least one territory: 57.1% (95% CI 56.3–58.0); men 63.4% versus women 50.9% (adjusted odds ratio 0.44 for women, 95% CI 0.40–0.48).
- Age 18–29: 8.7% of men and 6.7% of women; age 30–39: 34.6% of men and 21.3% of women.
- Adjusted odds ratio per 10-year increase in age: 4.52 (95% CI 4.21–4.87) in men and 3.85 (3.61–4.12) in women.
- In men prevalence rose from the 30–39 stratum and began to plateau by midlife; in women the steepest rise occurred after age 40, narrowing the sex difference.
- Among participants aged 60–70, only 1.9% of men and 8.1% of women had no plaque in any examined territory.
Vascular Distribution
- In younger participants, atherosclerosis was usually peripheral and confined to one territory, most often carotid.
- Carotid, femoral and coronary prevalence rose broadly in parallel in men; in women carotid disease predominated and femoral and coronary involvement occurred later.
- Isolated coronary atherosclerosis was uncommon in every age stratum: at most 9.3% of men and 5.0% of women.
- Among participants with coronary plaque, 82.0% also had peripheral plaque, versus 41.5% of those without coronary plaque.
- The odds of coronary atherosclerosis rose across peripheral plaque-volume quartiles (odds ratios 1.32, 1.85 and 3.70 versus no peripheral plaque).
- Multiterritorial disease increased with age: at 60–70, all three territories were involved in 56.3% of men and 30.7% of women.
Plaque Volume and Calcification
- Among participants with plaque, median carotid plaque volume was 23.9 mm³ (IQR 10.2–58.4), femoral 44.8 mm³ (16.0–120.3), combined peripheral 39.7 mm³ (13.4–116.6) and coronary 74.7 mm³ (32.0–181.4).
- Plaque volume increased with age in a pattern consistent with exponential growth; carotid and coronary plaque volume rose more steeply in men than women, while femoral growth was similar.
- Coronary plaque was frequently present without detectable calcium: among participants aged 30–39 with coronary plaque, 41.8% of men and 48.4% of women had a coronary calcium score of 0; this persisted, though less often, at ages 60–70.
Risk Classification
- Participants with silent atherosclerosis were older, had more risk factors and higher SCORE2 risk than those without plaque.
- SCORE2 high-risk classification identified only 0.5% of participants with single-territory disease and 3.8% of those with combined peripheral and coronary disease.
- High SCORE2 risk was highly specific (99.8%) but had low sensitivity (1.9%) for silent atherosclerosis; moderate-to-high SCORE2 risk had specificity 87.9% and sensitivity 34.1%.
- Discordance was greatest in younger participants and persisted after excluding participants on lipid-lowering or antihypertensive therapy.
Safety
- 115 adverse events and 10 serious adverse events were associated with study procedures.
Interpretation
- Silent atherosclerosis behaves as a systemic, progressive process; men develop the atherosclerotic phenotype about 5–10 years earlier than women.
- Because plaque predicts events independent of traditional risk factors, detection in young adults may identify people at increased long-term risk at a stage when risk-factor control has the greatest potential benefit.
- Imaging the carotid arteries had the highest diagnostic yield, but 18% of people with femoral but not carotid plaque would be missed by carotid imaging alone.
- Calcium scoring alone does not exclude early coronary atherosclerosis.
Limitations of the Document
- Cross-sectional design; age-related patterns are not within-person progression.
- Enrollment was stratified by age, sex and country, so the overall prevalence is a cross-sectional estimate rather than a population-weighted estimate.
- Complete three-territory imaging was available in 13,186 of 16,808 participants; incomplete imaging may introduce selection bias.
- The cohort excluded known clinical ASCVD and did not assess atherosclerosis outside the carotid, femoral and coronary territories.
- Healthy-participant bias may underestimate the true prevalence and extent of disease.
- Symptoms such as chest pain or claudication were not exclusion criteria, so some participants may have had symptomatic but undiagnosed disease.
Key Concepts Mentioned
- concepts/Subclinical-Atherosclerosis — the prevalence atlas, vascular distribution and screening implications
- concepts/Atherosclerosis-Pathophysiology — the underlying plaque biology
- concepts/ASCVD-Risk-Assessment — SCORE2, CAC scoring and risk reclassification
- concepts/Dyslipidemia — LDL-C and non-HDL-C as targets for primary prevention
Key Entities Mentioned
- entities/Obesity — a common risk factor in the cohort
- entities/Type-2-Diabetes — a risk factor and a driver of accelerated atherosclerosis
Wiki Pages Updated
wiki/sources/Silent-Atherosclerosis-NEJM-2026.md— created (this file)wiki/concepts/Subclinical-Atherosclerosis.md— createdwiki/concepts/Atherosclerosis-Pathophysiology.md— updated with the population imaging datawiki/concepts/ASCVD-Risk-Assessment.md— updated with the SCORE2–imaging discordancewiki/concepts/Dyslipidemia.md— linked to the new prevalence pagewiki/wikiindex.md— updatedwiki/sourceindex.md— updated